Author

Dirk Blom

Observed name: Blom, Dirk

Institution: University of Cape Town

Observed institution: University of Cape Town

OpenAlex ID: A5137119587

Pooled Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor, Across Two Phase 3 Trials: CORALreef Lipids and CORALreef HeFH

2026 · Christie Ballantyne, Elina Mikhailova, et al. · Journal of clinical lipidology · 1

Global Genetic Architecture of Familial Chylomicronaemia Syndrome: Insights from the FCS International Collaboration Project (FCS IP).

2026 · Atiqah Sapiyan, Bilal Bashir, et al. · Atherosclerosis Plus

Global Genetic Landscape of Familial Chylomicronaemia Syndrome: Insights From the Fcs International Collaboration Project (fcs Ip).

2026 · Atiqah Sapiyan, Bilal Bashir, et al. · Atherosclerosis

Genetic and Phenotypic Heterogeneity in Homozygous Familial Hypercholesterolemia: a Comprehensive Descriptive Analysis

2026 · Willemijn Schonck, Jana Koutna, et al. · Atherosclerosis

Global Risk of Pancreatic Complications in Familial Chylomicronaemia Syndrome (fcs) and Multifactorial Chylomicronaemia Syndrome (mcs): Initial Insights From the Fcs International Collaboration Project.

2026 · Atiqah Sapiyan, Bilal Bashir, et al. · Atherosclerosis

Long-term Safety and Effectiveness of Lomitapide in Treating Homozygous Familial Hypercholesterolemia: 11 Years of Real-world Evidence From the Lomitapide Observational Worldwide Evaluation Registry (lower)

2026 · Dirk Blom, Dominique Larrey, et al. · Atherosclerosis

Improving Care for Homozygous Familial Hypercholesterolaemia (hofh): Key Insights and Future Directions From the Global Hicc Registry

2026 · Willemijn Schonck, Janneke Mulder, et al. · Atherosclerosis

Bempedoic Acid in Children Aged 6-17 Years With Heterozygous Familial Hypercholesterolemia: a Phase 2 Study

2026 · Samuel Gidding, Paula Robinson, et al. · Atherosclerosis

The Long-term Efficacy and Safety of Lerodalcibep in Homozygous Familial Hypercholesterolaemia

2026 · Frederick Raal, Meral Kayikcioglu, et al. · Atherosclerosis

Effect of Enlicitide, an Oral Pcsk9 Inhibitor, on Apolipoprotein-b (apob) in Phase 3 Trials

2026 · Alberico Catapano, Min Zhou, et al. · Atherosclerosis

Long-term Follow-up Outcomes of Seven Patients With Homozygous Familial Hypercholesterolemia (hofh) Treated for ≥9 Years Included in the Lomitapide Observational Worldwide Evaluation Registry (lower)

2026 · Dirk Blom, Dominique Larrey, et al. · Atherosclerosis

Illness Perceptions, Psychological Well-being and Quality of Life in Homozygous Familial Hypercholesterolemia

2026 · Willemijn Schonck, Janneke Mulder, et al. · Atherosclerosis

Reproductive Experiences in Women and Men With Homozygous Familial Hypercholesterolemia

2026 · Janneke Mulder, Willemijn Schonck, et al. · Atherosclerosis

Long-Term Follow-Up Outcomes of 7 Patients with HoFH Treated ≥9 Years in the Lomitapide LOWER Registry

2026 · Dirk Blom, Dominique Larrey, et al. · Journal of clinical lipidology

Long-Term Safety and Effectiveness of Lomitapide in HoFH: 11 Years' Real-World Evidence from the Global LOWER Registry

2026 · Dirk Blom, Dominique Larrey, et al. · Journal of clinical lipidology

THU-012 MASLD in the WHOAfrica region: prevalence and development of a simple score to detect advanced fibrosis in dysmetabolic patients

2026 · Isabelle Bough, Bakary Dibba, et al. · Journal of Hepatology

Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor, for Lowering LDL Cholesterol in Adults with or At-Risk for ASCVD: The Phase 3 CORALreef Lipids Trial

· Navar, Ann Marie, Mikhailova, Elina, et al. · Institutional Repositories DataBase (IRDB)

Works count: 17

Citation count: 1

H-index: 1

I10-index: